Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of anti-TNF treatment on male fertility in inflammatory bowel disease
2008-005619-16Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab and adalimumab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Erasmus MC. Primary endpoints: Impact of anti-TNF agents on male fertility parameters and Pregnancy outcomes with paternal anti-TNF exposure. Started Apr 2009; status: active.
02
Drugs
infliximabadalimumab
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2008-005619-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005619-16.